Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Good manufacturing practice production of CD34+ progenitor-derived NK cells for adoptive immunotherapy in acute myeloid leukemia

Cancer Immunology Immunotherapy(2023)10.1007/s00262-023-03492-6Source: DataRank Database

Good manufacturing practice production of CD34+ progenitor-derived NK cells for adoptive immunotherapy in acute myeloid leukemia is a research paper published in Cancer Immunology Immunotherapy (2023). On theSindex it has a DataRank of 0. It has been cited 18 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access18 citations

Download PDF

Cite:

Linked data & code

cellosaurus gen eudract nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)OA: hybridTopics (35)IDs (PubMed, PMC)Annotations (4)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (15)

P.M.M. van Hauten ORCID,L. D. Janssen,Anna L. de Goede ORCID,Melissa M. Berrien-Elliott ORCID,Jolien M.R. Van der Meer ORCID

Live enrichment

PubMed:37477653 PMC:PMC10491545

KWF Kankerbestrijding

Grant: 10100

National Institutes of Health

Grant: R01CA205239

NCI NIH HHS

Grant: P50 CA171963

National Institutes of Health

Grant: 5R01CA205239-02

TRANSLATING NK CELL BIOLOGY INTO CLINICAL CANCER IMMUNOTHERAPY

National Institutes of Health

Grant: 5P50CA171963-09

Specialized Program Of Research Excellence (SPORE) in Leukemia.

hybridLicense: cc-by

publisherhttps://link.springer.com/content/pdf/10.1007/s00262-023-03492-6.pdf

publisherhttps://link.springer.com/article/10.1007/s00262-023-03492-6/fulltext.html

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10491545/pdf/262_2023_Article_3492.pdf

repositoryhttps://repository.ubn.ru.nl//bitstream/handle/2066/296528/296528.pdf

repositoryhttps://digitalcommons.wustl.edu/oa_4/3127

Fields of Study

03 medical and health sciences0302 clinical medicine

MeSH Terms

Killer Cells, NaturalHematopoietic Stem CellsHumansAntigens, CD34Immunotherapy, AdoptiveLeukemia, Myeloid, Acute

Keywords

ImmunotherapyAdoptive transferNatural Killer (Nk) CellsGood Manufacturing Practice (Gmp)Cell ManufacturingMyeloidAdoptiveRadboud University Medical CenterAntigens, CD34Radboudumc 2: Cancer development and immune defence Laboratory MedicineAcuteImmunotherapy, AdoptiveMedicine and Health SciencesRadboudumc 9: Rare cancers HaematologyKiller CellsHumansAntigensLeukemiaResearchICTS (Institute of Clinical and Translational Sciences)Hematopoietic Stem CellsKiller Cells, NaturalRadboudumc 2: Cancer development and immune defence HaematologyLeukemia, Myeloid, AcuteNaturalRadboudumc 4: lnfectious Diseases and Global Health Clinical PharmacyCD34

Sustainable Development Goals

SDG 3: 3. Good health

Good manufacturing practice production of CD34+ progenitor-derived NK cells for adoptive immunotherapy in acute myeloid leukemia

FAIR Checklist

Authors (15)

Funding (5 grants)

Open Access

Topics

Annotations (Europe PMC)